Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, place... von Tabernero, Josep, Hoff, Paulo M, Shen, Lin, Ohtsu, Atsushi, Shah, Manish A, Cheng, Karen, Song, Chunyan, Wu, Haiyan, Eng-Wong, Jennifer, Kim, Katherine, Kang, Yoon-Koo

Volltext

Corporate social responsibility and stakeholder value maximization: Evidence from mergers von Deng, Xin, Kang, Jun-koo, Low, Buen Sin

Volltext

A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data von Chen, Li-Tzong, Satoh, Taroh, Ryu, Min-Hee, Chao, Yee, Kato, Ken, Chung, Hyun Cheol, Chen, Jen-Shi, Muro, Kei, Kang, Won Ki, Yeh, Kun-Huei, Yoshikawa, Takaki, Oh, Sang Cheul, Bai, Li-Yuan, Tamura, Takao, Lee, Keun-Wook, Hamamoto, Yasuo, Kim, Jong Gwang, Chin, Keisho, Oh, Do-Youn, Minashi, Keiko, Cho, Jae Yong, Tsuda, Masahiro, Sameshima, Hiroki, Kang, Yoon-Koo, Boku, Narikazu

Volltext

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial von El-Khoueiry, Anthony B, Dr, Sangro, Bruno, MD, Yau, Thomas, MD, Crocenzi, Todd S, MD, Kudo, Masatoshi, MD, Hsu, Chiun, MD, Kim, Tae-You, MD, Choo, Su-Pin, BMBS, Trojan, Jörg, MD, Welling, Theodore H, MD, Meyer, Tim, MD, Kang, Yoon-Koo, MD, Yeo, Winnie, MD, Chopra, Akhil, MD, Anderson, Jeffrey, MD, dela Cruz, Christine, MD, Lang, Lixin, PhD, Neely, Jaclyn, PhD, Tang, Hao, PhD, Dastani, Homa B, PhD, Melero, Ignacio

Volltext

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocar... von Shitara, Kohei, Lordick, Florian, Bang, Yung-Jue, Enzinger, Peter, Ilson, David, Shah, Manish A, Van Cutsem, Eric, Xu, Rui-Hua, Aprile, Giuseppe, Xu, Jianming, Chao, Joseph, Pazo-Cid, Roberto, Kang, Yoon-Koo, Yang, Jianning, Moran, Diarmuid, Bhattacharya, Pranob, Arozullah, Ahsan, Park, Jung Wook, Oh, Mok, Ajani, Jaffer A

Volltext

The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines von Nishida, Toshirou, Blay, Jean-Yves, Hirota, Seiichi, Kitagawa, Yuko, Kang, Yoon-Koo

Volltext

Gastrointestinal stromal tumours von Blay, Jean-Yves, Kang, Yoon-Koo, Nishida, Toshiroo, von Mehren, Margaret

Volltext

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACT... von Kang, Yoon-Koo, Boku, Narikazu, Satoh, Taroh, Ryu, Min-Hee, Chao, Yee, Kato, Ken, Chung, Hyun Cheol, Chen, Jen-Shi, Muro, Kei, Kang, Won Ki, Yeh, Kun-Huei, Yoshikawa, Takaki, Oh, Sang Cheul, Bai, Li-Yuan, Tamura, Takao, Lee, Keun-Wook, Hamamoto, Yasuo, Kim, Jong Gwang, Chin, Keisho, Oh, Do-Youn, Minashi, Keiko, Cho, Jae Yong, Tsuda, Masahiro, Chen, Li-Tzong

Volltext

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an inter... von Thuss-Patience, Peter C, MD, Shah, Manish A, MD, Ohtsu, Atsushi, MD, Van Cutsem, Eric, Prof, Ajani, Jaffer A, Prof, Castro, Hugo, MD, Mansoor, Wasat, PhD, Chung, Hyun Cheol, Prof, Bodoky, Gyorgy, Prof, Shitara, Kohei, MD, Phillips, Gail D Lewis, MS, van der Horst, Tina, MSc, Harle-Yge, Marie-Laurence, MSc, Althaus, Betsy L, PharmD, Kang, Yoon-Koo, Prof

Volltext

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction ca... von Kang, Yoon-Koo, Chen, Li-Tzong, Ryu, Min-Hee, Oh, Do-Youn, Oh, Sang Cheul, Chung, Hyun Cheol, Lee, Keun-Wook, Omori, Takeshi, Shitara, Kohei, Sakuramoto, Shinichi, Chung, Ik-Joo, Yamaguchi, Kensei, Kato, Ken, Sym, Sun Jin, Kadowaki, Shigenori, Tsuji, Kunihiro, Chen, Jen-Shi, Bai, Li-Yuan, Oh, Sung-Yong, Choda, Yasuhiro, Yasui, Hisateru, Takeuchi, Kentaro, Hirashima, Yoshinori, Hagihara, Shunsuke, Boku, Narikazu

Volltext

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled,... von Zhu, Andrew X, Kang, Yoon-Koo, Yen, Chia-Jui, Finn, Richard S, Galle, Peter R, Llovet, Josep M, Assenat, Eric, Brandi, Giovanni, Pracht, Marc, Lim, Ho Yeong, Rau, Kun-Ming, Motomura, Kenta, Ohno, Izumi, Merle, Philippe, Daniele, Bruno, Shin, Dong Bok, Gerken, Guido, Borg, Christophe, Hiriart, Jean-Baptiste, Okusaka, Takuji, Morimoto, Manabu, Hsu, Yanzhi, Abada, Paolo B, Kudo, Masatoshi

Volltext

Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3) von Seo, Seyoung, Ryu, Min-Hee, Park, Young Soo, Ahn, Ji Yong, Park, Yangsoon, Park, Sook Ryun, Ryoo, Baek-Yeol, Lee, Gin Hyug, Jung, Hwoon-Young, Kang, Yoon-Koo

Volltext

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours von Hong, David S., Kang, Yoon-Koo, Borad, Mitesh, Sachdev, Jasgit, Ejadi, Samuel, Lim, Ho Yeong, Brenner, Andrew J., Park, Keunchil, Lee, Jae-Lyun, Kim, Tae-You, Shin, Sangjoon, Becerra, Carlos R., Falchook, Gerald, Stoudemire, Jay, Martin, Desiree, Kelnar, Kevin, Peltier, Heidi, Bonato, Vinicius, Bader, Andreas G., Smith, Susan, Kim, Sinil, O’Neill, Vincent, Beg, Muhammad S.

Volltext

EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the periopera... von Wagner, Anna Dorothea, Grabsch, Heike I, Mauer, Murielle, Marreaud, Sandrine, Caballero, Carmela, Thuss-Patience, Peter, Mueller, Lothar, Elme, Annelie, Moehler, Markus Hermann, Martens, Uwe, Kang, Yoon-Koo, Rha, Sun Young, Cats, Annemieke, Tokunaga, Masanori, Lordick, Florian

Volltext

Power Loss, System Efficiency, and Leakage Current Comparison Between Si IGBT VFD and SiC FET VFD With Various Filtering Options von Swamy, Mahesh M., Jun-Koo Kang, Shirabe, Kohei

Volltext

Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients... von Chung, Hyun Cheol, Kang, Yoon‐Koo, Chen, Zhendong, Bai, Yuxian, Wan Ishak, Wan Zamaniah, Shim, Byoung Yong, Park, Young Lee, Koo, Dong‐Hoe, Lu, Jianwei, Xu, Jianming, Chon, Hong Jae, Bai, Li‐Yuan, Zeng, Shan, Yuan, Ying, Chen, Yen‐Yang, Gu, Kangsheng, Zhong, Wen Yan, Kuang, Shu, Shih, Chie‐Schin, Qin, Shu‐Kui

Volltext

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial von Heinrich, Michael C, Jones, Robin L, von Mehren, Margaret, Schöffski, Patrick, Serrano, César, Kang, Yoon-Koo, Cassier, Philippe A, Mir, Olivier, Eskens, Ferry, Tap, William D, Rutkowski, Piotr, Chawla, Sant P, Trent, Jonathan, Tugnait, Meera, Evans, Erica K, Lauz, Tamieka, Zhou, Teresa, Roche, Maria, Wolf, Beni B, Bauer, Sebastian, George, Suzanne

Volltext

Management of gastric cancer in Asia: resource-stratified guidelines von Shen, Lin, Prof, Shan, Yan-Shen, Prof, Hu, Huang-Ming, MD, Price, Timothy J, Prof, Sirohi, Bhawna, DCH, Yeh, Kun-Huei, Prof, Yang, Yi-Hsin, PhD, Sano, Takeshi, MD, Yang, Han-Kwang, Prof, Zhang, Xiaotian, MD, Park, Sook Ryun, MD, Fujii, Masashi, Prof, Kang, Yoon-Koo, Prof, Chen, Li-Tzong, Prof

Volltext

Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial von Tabernero, Josep, Hoff, Paulo M., Shen, Lin, Ohtsu, Atsushi, Shah, Manish A., Siddiqui, Asna, Heeson, Sarah, Kiermaier, Astrid, Macharia, Harrison, Restuccia, Eleonora, Kang, Yoon-Koo

Volltext

Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study von Wainberg, Zev A, Enzinger, Peter C, Kang, Yoon-Koo, Qin, Shukui, Yamaguchi, Kensei, Kim, In-Ho, Saeed, Anwaar, Oh, Sang Cheul, Li, Jin, Turk, Haci Mehmet, Teixeira, Alexandra, Borg, Christophe, Hitre, Erika, Udrea, Adrian A, Cardellino, Giovanni Gerardo, Sanchez, Raquel Guardeño, Collins, Helen, Mitra, Siddhartha, Yang, Yingsi, Catenacci, Daniel V T, Lee, Keun-Wook

Volltext